C-reactive protein, lipoprotein (a) and cystatin C levels increase with multimorbidity in older persons

Garrafa, Emirena; Casnici, Niccolò; Squazzoni, Flaminio; Uberti, Daniela; Marengoni, Alessandra

doi:10.1016/j.ejim.2017.04.010

Cited by 6 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cross sectional data from the ongoing Italian prospective study by Fabbri and colleagues, looking at inflammatory and hormonal biomarkers, showed that higher serum IL-6, IL-1ra, TNF-α receptor II, and lower DHEA were associated cross-sectionally with higher number of diseases, independent of age, sex, body mass index, and education (Fabbri 2015a). Another study among community elderly in Italy examined the relationships of serum C-reactive protein, lipoprotein (a) and cystatin C levels and number of diseases present; it reported that higher values of all the three biomarkers correlated with a higher number of chronic conditions, both when dichotomized as high versus normal and as continuous variables (Garrafa 2017).…”

Section: Resultsmentioning

confidence: 99%

Biomarkers in the prediction of multimorbidity: scoping review

Spencer

Ford

Chan

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundMultimorbidity presents an increasing challenge in the global ageing population. Predicting its development is necessary to help design and deliver effective healthcare.ObjectiveThis scoping review aimed to collate and present the body of published evidence on biomarkers and multimorbidity, identifying what work has been done and what gaps remain.MethodsWe searched the electronic databases MEDLINE, Register of Controlled Trials (Cochrane CENTRAL), CINAHL, PsycINFO, EMBASE, Scopus, Web of Science and TRIP database up until 11 August 2020 and hand-searched the reference lists of included articles.ResultsWe found 34 relevant studies including 12 reporting prospective data and 22 reporting cross-sectional data. These encompassed 14 studies on serum biomarkers, 2 on molecular biomarkers, 7 on physiological biomarkers, 8 on body size biomarkers and 3 on brain function biomarkers. Most studies were undertaken in European or North American populations. There was a broadly consistent finding that obesity was associated with increased multimorbidity. Other results were more varied, reflecting the diverse range of biomarkers investigated, and lack of standardisation of multimorbidity outcome definitions.Longitudinal studies have been set up that are maturing and further evidence can be expected over time.ConclusionThere has been limited research on biomarkers to predict the development of multimorbidity, with minimal investigation of putative biomarkers identified in basic research. High quality research studies in this area are needed to progress the development of targeted interventions to prevent or delay the onset of multimorbidity.

show abstract

Section: Resultsmentioning

confidence: 99%

Biomarkers in the prediction of multimorbidity: scoping review

Spencer

Ford

Chan

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…People in the group of those with zero or one disease showed normal levels for the markers, as the number of chronic diseases increased the percentage of a person with a normal value of the markers decreased, showing that they are markers which can also be considered for detection of multimorbidity. 17 Three other studies also suggested CRP as a possible marker for multimorbidity, associating the increase of its concentration with two or more chronic conditions. 18 – 20 These data should be analyzed with caution, because cross-sectional and longitudinal studies have limitations to identify cause or consequence.…”

Section: Discussionmentioning

confidence: 99%

“…No randomized clinical trials (RCTs) were found in the search strategy, most part of the studies carried out observational analyses, and none cited a methodology including blind review. Nevertheless, from the 18 included studies, 15 presented a control group for comparability: patients who had only one of the morbidities of the study 16 – 24 , 27 , 28 , 30 , 33 or without morbidity (matched according to sex and age). 19 , 26 , 29 Although all included papers assessed association between at least two different morbidities, only five assessed specifically markers for multimorbidity in general regardless of the disease.…”

Section: Discussionmentioning

confidence: 99%

Physiological markers and multimorbidity

et al. 2018

View full text Add to dashboard Cite

Background:Multimorbidity is the co-occurrence of two or more diseases in the same individual. One method to identify this condition at an early stage is the use of specific markers for various combinations of morbidities. Nonetheless, evidence related to physiological markers in multimorbidity is limited.Objective:The aim was to perform a systematic review to identify physiological markers associated with multimorbidity.Design:Articles available on PubMed, Register of Controlled Trials, Academic Search Premier, CINAHL, Scopus, SocINDEX, Web of Science, LILACS, and SciELO, from their inception to May 2018, were systematically searched and reviewed. The project was registered in PROSPERO under the number CRD42017055522.Results:The systematic search identified 922 papers. After evaluation, 18 articles were included in the full review reporting at least one physiological marker in coexisting diseases or which are strongly associated with the presence of multimorbidity in the future. Only five of these studies examined multimorbidity in general, identifying five physiological markers associated with multimorbidity, namely, dehydroepiandrosterone sulfate (DHEAS), interleukin 6 (IL-6), C-reactive protein (CRP), lipoprotein (Lp), and cystatin C (Cyst-C).Conclusions:There is a paucity of studies related to physiological markers in multimorbidity. DHEAS, IL-6, CRP, Lp, and Cyst-C could be the initial focus for further investigation of physiological markers related to multimorbidity.

show abstract

“…Table 2). Cys-C is a cysteine proteases inhibitor ubiquitously expressed and secreted into all body fluids [15, 32]. It has been proposed as a regulator of several cellular functions, such as apoptosis, autophagy, and inflammatory response [16].…”

Section: Discussionmentioning

confidence: 99%

Plasma Cystatin C Correlates with Plasma NfL Levels and Predicts Disease Progression in Parkinson’s Disease

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction: Previous studies reported increased plasma levels of Cystatin C (Cys-C) in Parkinson’s disease (PD) and claimed for a possible association with disease severity and progression. The aim of this study was to evaluate plasma Cys-C in PD and healthy controls (HC) and test its association with markers of peripheral inflammation, neurodegeneration and clinical progression in a longitudinal study. Methods: Plasma Cys-C, high-sensitive C-reactive protein (hsCRP), interleukin 6 (IL-6) and Neurofilament Light Chain (NfL) were assessed at the baseline in 71 consecutive non-demented PD and 69 HC. PD patients underwent an extensive motor and cognitive assessment at baseline and after 2 years of follow-up. The association of Cys-C with disease severity was evaluated in a multilinear model adjusted for the effect of age, sex, disease duration and peripheral inflammation. Results: Cys-C levels appeared to be higher in PD compared to controls and correlated with the plasma neuronal marker NfL (r = 0.204, p = 0.046). In longitudinal analyses, PD patients with higher Cys-C levels exhibited faster motor progression at two years of follow-up independently from the peripheral inflammatory profile. Conclusions: Cys-C was associated with higher NfL levels and a remarkably faster motor progression in PD independently from peripheral inflammation. Further studies are needed in order to understand the mechanisms underpinning the association of Cys-C with higher neuronal damage markers in neurodegenerative diseases.

show abstract

C-reactive protein, lipoprotein (a) and cystatin C levels increase with multimorbidity in older persons

Cited by 6 publications

References 8 publications

Biomarkers in the prediction of multimorbidity: scoping review

Biomarkers in the prediction of multimorbidity: scoping review

Physiological markers and multimorbidity

Plasma Cystatin C Correlates with Plasma NfL Levels and Predicts Disease Progression in Parkinson’s Disease

Contact Info

Product

Resources

About